KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization

Passive transfer studies in humans clearly demonstrated the protective role of IgG antibodies against malaria. Identifying the precise parasite antigens that mediate immunity is essential for vaccine design, but has proved difficult. Completion of the Plasmodium falciparum genome revealed thousands...

Full description

Bibliographic Details
Main Authors: Kamuyu, G, Tuju, J, Kimathi, R, Mwai, K, Mburu, J, Kibinge, N, Kwan, M, Hawkings, S, Yaa, R, Chepsat, E, Njunge, J, Chege, T, Guleid, F, Rosenkranz, M, Kariuki, C, Frank, R, Kinyanjui, S, Murungi, L, Bejon, P, Farnert, A, Tetteh, K, Beeson, J, Conway, D, Marsh, K, Rayner, J, Osier, F
Format: Journal article
Published: Frontiers Media 2018
_version_ 1797054612294860800
author Kamuyu, G
Tuju, J
Kimathi, R
Mwai, K
Mburu, J
Kibinge, N
Kwan, M
Hawkings, S
Yaa, R
Chepsat, E
Njunge, J
Chege, T
Guleid, F
Rosenkranz, M
Kariuki, C
Frank, R
Kinyanjui, S
Murungi, L
Bejon, P
Farnert, A
Tetteh, K
Beeson, J
Conway, D
Marsh, K
Rayner, J
Osier, F
author_facet Kamuyu, G
Tuju, J
Kimathi, R
Mwai, K
Mburu, J
Kibinge, N
Kwan, M
Hawkings, S
Yaa, R
Chepsat, E
Njunge, J
Chege, T
Guleid, F
Rosenkranz, M
Kariuki, C
Frank, R
Kinyanjui, S
Murungi, L
Bejon, P
Farnert, A
Tetteh, K
Beeson, J
Conway, D
Marsh, K
Rayner, J
Osier, F
author_sort Kamuyu, G
collection OXFORD
description Passive transfer studies in humans clearly demonstrated the protective role of IgG antibodies against malaria. Identifying the precise parasite antigens that mediate immunity is essential for vaccine design, but has proved difficult. Completion of the Plasmodium falciparum genome revealed thousands of potential vaccine candidates, but a significant bottleneck remains in their validation and prioritization for further evaluation in clinical trials. Focusing initially on the Plasmodium falciparum merozoite proteome, we used peer-reviewed publications, multiple proteomic and bioinformatic approaches, to select and prioritize potential immune targets. We expressed 109 P. falciparum recombinant proteins, the majority of which were obtained using a mammalian expression system that has been shown to produce biologically functional extracellular proteins, and used them to create KILchip v1.0: a novel protein microarray to facilitate high-throughput multiplexed antibody detection from individual samples. The microarray assay was highly specific; antibodies against P. falciparum proteins were detected exclusively in sera from malaria-exposed but not malaria-naïve individuals. The intensity of antibody reactivity varied as expected from strong to weak across well-studied antigens such as AMA1 and RH5 (Kruskal–Wallis H test for trend: p < 0.0001). The inter-assay and intra-assay variability was minimal, with reproducible results obtained in re-assays using the same chip over a duration of 3 months. Antibodies quantified using the multiplexed format in KILchip v1.0 were highly correlated with those measured in the gold-standard monoplex ELISA [median (range) Spearman's R of 0.84 (0.65–0.95)]. KILchip v1.0 is a robust, scalable and adaptable protein microarray that has broad applicability to studies of naturally acquired immunity against malaria by providing a standardized tool for the detection of antibody correlates of protection. It will facilitate rapid high-throughput validation and prioritization of potential Plasmodium falciparum merozoite-stage antigens paving the way for urgently needed clinical trials for the next generation of malaria vaccines.
first_indexed 2024-03-06T18:59:39Z
format Journal article
id oxford-uuid:1312794f-d80d-453d-b776-febdc563da52
institution University of Oxford
last_indexed 2024-03-06T18:59:39Z
publishDate 2018
publisher Frontiers Media
record_format dspace
spelling oxford-uuid:1312794f-d80d-453d-b776-febdc563da522022-03-26T10:11:50ZKILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritizationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1312794f-d80d-453d-b776-febdc563da52Symplectic Elements at OxfordFrontiers Media2018Kamuyu, GTuju, JKimathi, RMwai, KMburu, JKibinge, NKwan, MHawkings, SYaa, RChepsat, ENjunge, JChege, TGuleid, FRosenkranz, MKariuki, CFrank, RKinyanjui, SMurungi, LBejon, PFarnert, ATetteh, KBeeson, JConway, DMarsh, KRayner, JOsier, FPassive transfer studies in humans clearly demonstrated the protective role of IgG antibodies against malaria. Identifying the precise parasite antigens that mediate immunity is essential for vaccine design, but has proved difficult. Completion of the Plasmodium falciparum genome revealed thousands of potential vaccine candidates, but a significant bottleneck remains in their validation and prioritization for further evaluation in clinical trials. Focusing initially on the Plasmodium falciparum merozoite proteome, we used peer-reviewed publications, multiple proteomic and bioinformatic approaches, to select and prioritize potential immune targets. We expressed 109 P. falciparum recombinant proteins, the majority of which were obtained using a mammalian expression system that has been shown to produce biologically functional extracellular proteins, and used them to create KILchip v1.0: a novel protein microarray to facilitate high-throughput multiplexed antibody detection from individual samples. The microarray assay was highly specific; antibodies against P. falciparum proteins were detected exclusively in sera from malaria-exposed but not malaria-naïve individuals. The intensity of antibody reactivity varied as expected from strong to weak across well-studied antigens such as AMA1 and RH5 (Kruskal–Wallis H test for trend: p < 0.0001). The inter-assay and intra-assay variability was minimal, with reproducible results obtained in re-assays using the same chip over a duration of 3 months. Antibodies quantified using the multiplexed format in KILchip v1.0 were highly correlated with those measured in the gold-standard monoplex ELISA [median (range) Spearman's R of 0.84 (0.65–0.95)]. KILchip v1.0 is a robust, scalable and adaptable protein microarray that has broad applicability to studies of naturally acquired immunity against malaria by providing a standardized tool for the detection of antibody correlates of protection. It will facilitate rapid high-throughput validation and prioritization of potential Plasmodium falciparum merozoite-stage antigens paving the way for urgently needed clinical trials for the next generation of malaria vaccines.
spellingShingle Kamuyu, G
Tuju, J
Kimathi, R
Mwai, K
Mburu, J
Kibinge, N
Kwan, M
Hawkings, S
Yaa, R
Chepsat, E
Njunge, J
Chege, T
Guleid, F
Rosenkranz, M
Kariuki, C
Frank, R
Kinyanjui, S
Murungi, L
Bejon, P
Farnert, A
Tetteh, K
Beeson, J
Conway, D
Marsh, K
Rayner, J
Osier, F
KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
title KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
title_full KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
title_fullStr KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
title_full_unstemmed KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
title_short KILchip v1.0: a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
title_sort kilchip v1 0 a novel plasmodium falciparum merozoite protein microarray to facilitate malaria vaccine candidate prioritization
work_keys_str_mv AT kamuyug kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT tujuj kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT kimathir kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT mwaik kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT mburuj kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT kibingen kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT kwanm kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT hawkingss kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT yaar kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT chepsate kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT njungej kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT cheget kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT guleidf kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT rosenkranzm kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT kariukic kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT frankr kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT kinyanjuis kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT murungil kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT bejonp kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT farnerta kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT tettehk kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT beesonj kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT conwayd kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT marshk kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT raynerj kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization
AT osierf kilchipv10anovelplasmodiumfalciparummerozoiteproteinmicroarraytofacilitatemalariavaccinecandidateprioritization